Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR)

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. received an amended Schedule 13G/A disclosing that Morgan Stanley and Morgan Stanley Capital Services LLC each report beneficial ownership below 5% of Voting Common Stock. The filing shows 1,333,420 shares (4.8%) attributed to Morgan Stanley and 1,294,420 shares (4.6%) attributed to Morgan Stanley Capital Services LLC, with both entities stating they have ceased to be beneficial owners of more than five percent.

Insights

Institutional Ownership Analyst

Large fiduciary positions fall below 5% reporting threshold.

The amendment lists 1,333,420 shares (4.8%) for Morgan Stanley and 1,294,420 shares (4.6%) for Morgan Stanley Capital Services LLC. These percentages indicate both reporting units now fall under the 5% beneficial‑ownership reporting level.

Implications depend on trading activity by those MS reporting units; subsequent Form 13 filings would disclose any renewed thresholds or material changes.

Corporate Governance Specialist

Administrative amendment clarifies ownership status; no corporate action disclosed.

The filing is an Amendment No. 1 to a Schedule 13G, signed by an authorized signatory, and includes Exhibits 99.1 and 99.2. It follows the SEC release framework for aggregated reporting by MS reporting units.

Governance effects are procedural: this restates threshold status and attaches subsidiary identification per Item 7; it does not indicate proxy or control changes.

Key Figures

Morgan Stanley shares: 1,333,420 shares Morgan Stanley percent: 4.8 % Morgan Stanley Capital Services shares: 1,294,420 shares +3 more

6 metrics

Morgan Stanley shares 1,333,420 shares reported beneficially owned amount

Morgan Stanley percent 4.8 % percent of class reported

Morgan Stanley Capital Services shares 1,294,420 shares reported beneficially owned amount

Morgan Stanley Capital Services percent 4.6 % percent of class reported

CUSIP 471871202 Voting Common Stock CUSIP

Authorized signatory date 05/12/2026 signature date for amendment

Key Terms

Schedule 13G/A, beneficial owner, MS Reporting Units, Joint Filing Agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 to Schedule 13G/A disclosing beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial owner regulatory

"has ceased to be the beneficial owner of more than five percent of the class"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

MS Reporting Units financial

"securities beneficially owned by certain operating units (the "MS Reporting Units")"

Joint Filing Agreement regulatory

"Exhibit 99.1 Joint Filing Agreement"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Jasper Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock

(Title of Class of Securities)

471871202

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 471871202

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,333,220.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,333,420.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,333,420.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

CUSIP Number(s): 471871202

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,294,420.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,294,420.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,294,420.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

BD, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley Capital Services LLC has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Jasper Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Voting Common Stock
(e)	CUSIP No.: 471871202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 4.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	05/12/2026

Morgan Stanley Capital Services LLC

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	05/12/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

What does the Jasper Therapeutics (JSPR) Schedule 13G/A say about Morgan Stanley's stake?

It reports 1,333,420 shares (4.8%) attributed to Morgan Stanley. The filing states Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class.

How many shares does Morgan Stanley Capital Services LLC report owning in JSPR?

Morgan Stanley Capital Services LLC reports 1,294,420 shares (4.6%). The filing indicates it has ceased to be the beneficial owner of more than five percent of the class.

Does this Schedule 13G/A indicate Morgan Stanley gained control of Jasper Therapeutics?

No. The amendment reports percentage ownership below 5% for the MS reporting units and contains no statements claiming control or a change in governance authority.

What exhibits accompany this Schedule 13G/A amendment for JSPR?

The filing lists Exhibit 99.1 (Joint Filing Agreement) and Exhibit 99.2 (Item 7 subsidiary identification information) attached to the amendment.

Who signed the Schedule 13G/A amendment for Jasper Therapeutics?

The amendment is signed by Claire Gordon as Authorized Signatory for Morgan Stanley and for Morgan Stanley Capital Services LLC, each dated 05/12/2026.